Abrha Solomon, Tesfaye Wubshet, Thomas Jackson
Faculty of Health, University of Canberra, Canberra, ACT 2617, Australia.
Department of Pharmaceutics, School of Pharmacy, College of Health Sciences, Mekelle University, Mekelle 7000, Ethiopia.
Antibiotics (Basel). 2020 Dec 15;9(12):909. doi: 10.3390/antibiotics9120909.
Impetigo (school sores) is a common superficial bacterial skin infection affecting around 162 million children worldwide, with the highest burden in Australian Aboriginal children. While impetigo itself is treatable, if left untreated, it can lead to life-threatening conditions, such as chronic heart and kidney diseases. Topical antibiotics are often considered the treatment of choice for impetigo, but the clinical efficacy of these treatments is declining at an alarming rate due to the rapid emergence and spread of resistant bacteria. In remote settings in Australia, topical antibiotics are no longer used for impetigo due to the troubling rise of antimicrobial resistance, demanding the use of oral and injectable antibiotic therapies. However, widespread use of these agents not only contributes to existing resistance, but also associated with adverse consequences for individuals and communities. These underscore the urgent need to reinvigorate the antibiotic discovery and alternative impetigo therapies in these settings. This review discusses the current impetigo treatment challenges in endemic settings in Australia and explores potential alternative antimicrobial therapies. The goals are to promote intensified research programs to facilitate effective use of currently available treatments, as well as developing new alternatives for impetigo.
脓疱病(学校疮)是一种常见的浅表细菌性皮肤感染,全球约有1.62亿儿童受其影响,澳大利亚原住民儿童的负担最重。虽然脓疱病本身是可治疗的,但如果不治疗,可能会导致危及生命的疾病,如慢性心脏病和肾病。外用抗生素通常被认为是脓疱病的首选治疗方法,但由于耐药菌的迅速出现和传播,这些治疗方法的临床疗效正以惊人的速度下降。在澳大利亚的偏远地区,由于抗菌药物耐药性的令人担忧的上升,外用抗生素不再用于治疗脓疱病,因此需要使用口服和注射用抗生素疗法。然而,这些药物的广泛使用不仅会导致现有的耐药性,还会给个人和社区带来不良后果。这些都凸显了在这些地区重振抗生素研发和寻找脓疱病替代疗法的迫切需求。本综述讨论了澳大利亚地方病流行地区目前脓疱病治疗面临的挑战,并探讨了潜在的替代抗菌疗法。目标是促进强化研究项目,以促进有效使用目前可用的治疗方法,同时开发脓疱病的新替代疗法。